Latest News
Eli Lilly and Company
- Eli Lilly Partners with METiS TechBio in Up to $1.1 Bn AI Drug Delivery Deal
- Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck
- Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
- METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies
- HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion
- Eli Lilly and Co. | Pharmaceuticals, Biomedical Research, & Company
- Eli Lilly: Buy The GLP-1 Growth Premium
- Eli Lilly and Company CEO Dave Ricks tells CNBC-TV18's Shereen Bhan that the launch of cheaper branded generic semaglutide in India — priced far below Mounjaro — hasn't changed the company's trajectory, calling ultra-low price points "a bit of a fake sig
- Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results
- Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
- Eli Lilly is partnering with China's InnoCare on a drug deal worth up to $3.35 billion
Headlines from the last 30 days, linking to the original publishers. See all market news →